Literature DB >> 3455878

Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course.

F Vánky, E Klein, J Willems, K Böök, T Ivert, A Péterffy, U Nilsonne, A Kreicbergs, T Aparisi.   

Abstract

Lymphocyte-mediated lysis of autologous tumor cells (autologous lymphocyte cytotoxicity ALC) was tested at the time of surgery in 108 patients (46 squamous cell carcinomas of the lung, 25 adenocarcinomas of the lung, 19 soft tissue sarcomas and 18 osteosarcomas). The clinical course of these patients in relation to the test results has been published previously. The group was evaluated again after an extended observation time, now with a mean of 80.2 months (range 36-108). The test was rarely positive in patients with metastasis (2 out of 28 experiments). There was a correlation between the ALC results and the postsurgical clinical course for patients without detectable metastasis in that (1) a negative test was invariably a bad prognostic sign, i.e., all 32 patients with negative ALC died within 3 years (mean survival time 16.1 months). (2) The remission and survival times were longer for the ALC positive patients (p less than 0.001). (3) All 37 individuals who are alive at present without recurrence belong to the reactive group. The ALC results correlated with the clinical course in 88% of patients. The correlation was highest for the groups of soft tissue sarcoma and adenocarcinoma of the lung. There was no correlation between killing of K562 cells and ALC, or between lymphoproliferative response to PHA and ALC reactivity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3455878     DOI: 10.1007/BF00199380

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Adjuvant interferon treatment of human osteosarcoma.

Authors:  H Strander; U Adamson; T Aparisi; L A Broström; K Cantell; S Einhorn; K Hall; S Ingimarsson; U Nilsonne; G Söderberg
Journal:  Recent Results Cancer Res       Date:  1978

2.  Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course. I. Evaluation of 46 patients with sarcoma.

Authors:  F Vánky; J Willems; A Kreicbergs; T Aparisi; M Andréen; L A Broström; U Nilsonne; E Klein; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

3.  Specific T-cell-mediated killing of autologous lung tumour cells.

Authors:  B M Vose
Journal:  Cell Immunol       Date:  1980-09-15       Impact factor: 4.868

4.  Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. II. Evaluation of 69 patients with lung carcinoma.

Authors:  F Vánky; A Péterffy; K Böök; J Willems; E Klein; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes.

Authors:  F Vánky; E Klein
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

6.  Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes.

Authors:  G Fossati; A Balsari; D Taramelli; M L Sensi; G Pellegris; M Nava; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients to mitogens and alloantigens.

Authors:  J H Dean; R Connor; R B Herberman; J Silva; J L McCoy; R K Oldham
Journal:  Int J Cancer       Date:  1977-09-15       Impact factor: 7.396

8.  Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity.

Authors:  F T Vánky; B M Vose; M Fopp; E Klein
Journal:  J Natl Cancer Inst       Date:  1979-06       Impact factor: 13.506

9.  Restricted autologous lymphocytotoxicity in lung neoplasia.

Authors:  B M Vose; F Vánky; M Fopp; E Klein
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

10.  Specific and non-specific lymphocyte cytotoxicity in colon carcinoma.

Authors:  B M Vose; P Gallagher; M Moore; P F Schofield
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

View more
  11 in total

1.  Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells.

Authors:  F Vánky; G Stuber; S Rotstein; E Klein
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity.

Authors:  F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells.

Authors:  F Vánky; P Wang; E Klein
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  The Antibody Repertoire of Colorectal Cancer.

Authors:  Seong Won Cha; Stefano Bonissone; Seungjin Na; Pavel A Pevzner; Vineet Bafna
Journal:  Mol Cell Proteomics       Date:  2017-10-18       Impact factor: 5.911

5.  Expression of interleukin-2 receptor on blood lymphocytes stimulated with allogeneic lymphocytes or autologous tumor cells. The mixed lymphocyte culture of allo-sensitized individuals and the auto-tumor stimulation show similar kinetics of activation.

Authors:  G Stuber; F Vánky; E Pócsik; M Benczúr; E Klein
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 6.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Cyclophosphamide modifies the induction kinetics but not cell types and cytotoxic mechanisms of antitumor cells elicited with OK-432 plus attenuated tumor cells.

Authors:  K Ryoyama; C Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture--no correlation with the postsurgical clinical course.

Authors:  F Vánky; E Klein; J Willems; K Böök; T Ivert; A Péterffy; U Nilsonne; A Kreicbergs
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Importance of MHC antigen expression on solid tumors in the in vitro interaction with autologous blood lymphocytes.

Authors:  F Vánky; G Stuber; J Willems; K Sjöwall; B Larsson; K Böök; T Ivert; A Péterffy; E Klein
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro.

Authors:  F Vánky; P Wang; M Patarroyo; E Klein
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.